You are hereEvents
Individualized Genomic Approaches For Safer And More Effective Patient-Tailored Medications: Focus On Heart Toxicity From The Treatment Of Childhood Cancer
My research seeks to improve the lives of patients by developing new tools for safer and more effective use of medications based upon an individual’s genetic blueprint. The debilitating and sometimes lethal consequences of severe adverse drug reactions (ADRs) are a striking problem. The overarching goals of my research are to identify the genetic and/or clinical factors of severe ADRs so that in the future these ADRs could be prevented by identifying those patients at greatest risk before a drug is administered. My presentation will provide a background on what are ADRs, and how genetic factors can contribute to ADR susceptibility, and we will focus on an example ADR caused by anthracyclines that can cause serious heart toxicity on some patients, as well as new approaches that are underway to mitigate this toxicity.
C2E2 Rounds are presented Mondays from 12:00 pm to 1:00 pm in room 700 of the VGH Research Pavilion, 828 West 10th Avenue, Vancouver, BC.